Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78833
Title:
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
Authors:
Braun, M S; Adab, Fawzi; Bradley, C; McAdam, K; Thomas, G; Wadd, N J; Rea, D; Philips, R; Twelves, C; Bozzino, J; MacMillan, C; Saunders, Mark P; Counsell, R; Anderson, Heather; McDonald, A; Stewart, J; Robinson, A; Davies, S; Richards, F J; Seymour, M T
Abstract:
We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.
Affiliation:
Cancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK.
Citation:
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. 2003, 89 (7):1155-8 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
6-Oct-2003
URI:
http://hdl.handle.net/10541/78833
DOI:
10.1038/sj.bjc.6601237
PubMed ID:
14520437
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBraun, M S-
dc.contributor.authorAdab, Fawzi-
dc.contributor.authorBradley, C-
dc.contributor.authorMcAdam, K-
dc.contributor.authorThomas, G-
dc.contributor.authorWadd, N J-
dc.contributor.authorRea, D-
dc.contributor.authorPhilips, R-
dc.contributor.authorTwelves, C-
dc.contributor.authorBozzino, J-
dc.contributor.authorMacMillan, C-
dc.contributor.authorSaunders, Mark P-
dc.contributor.authorCounsell, R-
dc.contributor.authorAnderson, Heather-
dc.contributor.authorMcDonald, A-
dc.contributor.authorStewart, J-
dc.contributor.authorRobinson, A-
dc.contributor.authorDavies, S-
dc.contributor.authorRichards, F J-
dc.contributor.authorSeymour, M T-
dc.date.accessioned2009-08-27T09:11:30Z-
dc.date.available2009-08-27T09:11:30Z-
dc.date.issued2003-10-06-
dc.identifier.citationModified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. 2003, 89 (7):1155-8 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid14520437-
dc.identifier.doi10.1038/sj.bjc.6601237-
dc.identifier.urihttp://hdl.handle.net/10541/78833-
dc.description.abstractWe previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshLeucovorin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshOrganoplatinum Compounds-
dc.subject.meshProspective Studies-
dc.subject.meshSurvival Rate-
dc.subject.meshTime Factors-
dc.titleModified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.